Table 3.
Detection of HPV-positive cells in semen, seroconversion and antibody titre of both patients of the control arm and non-vaccine sensitive patients.
| Seronegative VSP (N = 30) |
NVSP (N = 88) |
Seroconverted VSP (N = 19) |
||||
|---|---|---|---|---|---|---|
| Time-point | % HPV + cells (mean ± SD) |
Seroconverted patients (gm titre ± SD) |
% HPV + cells (mean ± SD) |
Seroconverted patients (gm titre ± SD) |
% HPV + cells (mean ± SD) |
Seroconverted patients (gm mean titre ± SD) |
| t0 | 22.1 ± 5.6 | 0 | 27 ± 6.4 | 2/43 (1:65 ± 58) |
11.6 ± 3.2%* | 19 (1:58 ± 34n.a.) |
| t6 | 14.5 ± 4.2 | 0 | 11 ± 7.2 | 3/43 (1:42 ± 73) |
8.0 ± 1.7%* | 19 (1:66 ± 56n.a.) |
| t12 | 16.1 ± 8.1 | 1 (1:72) |
10 ± 9.3 | 1/43 (1:126) |
3.3 ± 2.1%* | 19 (1:85 ± 43n.a.) |
| t18 | 8.1 ± 3.8 | 3 (1:62 ± 37) |
6.2 ± 5.6 | 2/43 (1:55 ± 41) |
5%n.a. | 19 (1:92 ± 67n.s.) |
| t24 | 4.8 ± 3.4 | 3 (1:94 ± 21) |
4.1 ± 3.4 | 3/43 (1:94 ± 21) |
0%n.a. | 19 (1:98 ± 71n.s.) |
Abbreviations: t0: recruitment; t6, t12, t18, t24: 6, 12, 18 and 24 months from recruitment respectively; % HPV + cells: percentage of HPV-DNA positive-spermatozoa; VSP: vaccine sensitive patients; NVSP: nonvaccine-sensitive patients; gm titre: geometric mean of the antibody titre; SD: standard deviation of the mean.
Significance: n.a. = not available; * = P < 0·05 vs seronegative VSP; n.s. = P ≥ 0·05 vs seronegative VSP.